Proteases

BI-1942 is a potent chymase inhibitor with an IC50 of 0.4 nM for human chymase. This chemical probe is primarily utilized in research related to ophthalmic diseases, enabling the exploration of chymase's role in ocular pathologies. Its selective inhibition provides a valuable tool for investigating the therapeutic potential in conditions where chymase is implicated.

RID-F (Ridaifen-F) is a nonpeptidic proteasome inhibitor that targets the human 20S proteasome. It demonstrates significant inhibitory activity with IC50 values of 0.64 µM for caspase-like (CT-L), 0.34 µM for trypsin-like (T-L), and 0.43 µM for post-glutamyl (PGPH) activities. RID-F is utilized in research focused on cellular degradation pathways, cancer biology, and therapeutic approaches targeting proteasome dysfunction.

Chymase-IN-2 is a potent proteasome inhibitor that selectively modulates chymase activity. It exhibits significant efficacy in addressing inflammatory responses and disorders associated with serine protease activity. This compound is valuable for research aimed at understanding protease-mediated pathways and their implications in various diseases.

Neurodegenerative Disorder-Targeting Compound 1 is a proteasome inhibitor that selectively targets calpain activity. This compound is designed to modulate cellular protein turnover, making it a valuable tool for studying the mechanisms of neurodegeneration. Its application spans various research areas, including the investigation of proteolytic pathways in neurodegenerative disorders and the exploration of therapeutic interventions aimed at enhancing neuronal survival.

Ru(acac)3 (Tris(acetylacetonato)ruthenium(III)) acts as a caspase-3 activator and apoptosis inducer. This compound demonstrates growth inhibitory effects on various cell lines in vitro, primarily by inhibiting DNA/RNA synthesis and inducing a mild, reversible S-phase cell cycle arrest. Ru(acac)3 is utilized in research focused on ovarian cancer, osteosarcoma, cervical cancer, melanoma, and other oncological studies.

β-Ala-Gly-Arg-pNA is a chromogenic substrate specifically designed for thrombin activity assays. It releases para-nitroaniline (pNA) upon cleavage, generating a measurable absorbance peak at 405 nm. This substrate is valuable in studies of thrombin activity and inhibition, enabling researchers to assess coagulation mechanisms and related pathological conditions accurately.

Apigenin-7-glucuronide is a potent inhibitor of Matrix Metalloproteinases (MMP), demonstrating IC50 values of 12.87 µM for MMP-3, 22.39 µM for MMP-8, 17.52 µM for MMP-9, and 0.27 µM for MMP-13. This compound's ability to modulate MMP activity makes it valuable for investigations into extracellular matrix regulation, tissue remodeling, and various inflammatory conditions. Researchers may utilize Apigenin-7-glucuronide in studies aiming to explore therapeutic interventions in diseases associated with MMP dysregulation.

Luteolin 7-O-glucuronide is a potent inhibitor of Matrix Metalloproteinases (MMPs), demonstrating IC50 values of 17.63 μM for MMP-1, 7.99 μM for MMP-3, 11.42 μM for MMP-8, 12.85 μM for MMP-9, and 0.03 μM for MMP-13. This compound is valuable for research investigating the regulation of MMP activity, which plays a critical role in extracellular matrix remodeling and various pathological conditions. It is suitable for applications in studies related to cancer metastasis, tissue repair, and inflammatory disorders.

Argatroban monohydrate is a direct and selective inhibitor of thrombin. It plays a critical role in anticoagulation therapy, particularly for patients with heparin-induced thrombocytopenia. Argatroban is widely used in research to study coagulation pathways and evaluate potential therapeutic approaches for thrombotic disorders.

α-Arbutin (4-Hydroxyphenyl α-D-glucopyranoside) is a potent tyrosinase inhibitor known for its ability to reduce melanin production, making it a valuable agent in skin lightening applications. This compound is of significant interest in research surrounding hyperpigmentation disorders, various cancer types, central nervous system disorders, osteoporosis, and diabetes, offering potential therapeutic insights into these conditions. Its mechanism of action provides a basis for exploring innovative treatments and understanding skin-related pathologies.

Methyl cinnamate (Methyl 3-phenylpropenoate) is an effective tyrosinase inhibitor, primarily utilized to prevent enzymatic browning in food products. In addition to its role in food applications, it demonstrates antimicrobial properties and exhibits antiadipogenic effects, partly mediated by the CaMKK2-AMPK signaling pathway. This compound is valuable for researchers exploring therapeutic strategies in skin pigmentation disorders and metabolic regulation.